Wow great results for COPD sufferers. I know from personal relationships the lack of therapies for this disease.
So a side benifit of this covid trial is that a therapy for COPD could come to market quicker.
Also I am impressed with the new biomarker data that identifies who will benefit. At this time our therapy is quite expensive.
Personalized medicine will help make sure health care dollars are not wasted.
The new argument is that cell therapies are to expensive. Fact is in 10 years cheaper versions will be allowed on the market. We are changing health care in the same way as penicillin and vaccines.
Good luck fellow visionaries
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-109
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $18.34M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 104582 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 56681 | 17 |
View Market Depth
| Last trade - 15.07pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |